Core Scientific (CORZ) Cash from Financing Activities (2021 - 2026)

Core Scientific has disclosed Cash from Financing Activities across 6 years of filings, most recently posting $971.4 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $971.4 million, up 23239.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $912.5 million (up 19.9% YoY), and the FY2025 annual result was -$63.1 million, down 107.7% from the prior year.
• Cash from Financing Activities came in at $971.4 million for Q1 2026 at Core Scientific, up from -$21.8 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $971.4 million in Q1 2026 to a low of -$45.1 million in Q3 2022.
• The 5-year median for Cash from Financing Activities is -$4.2 million (2025), against an average of $117.0 million.
• Across the five-year window, Cash from Financing Activities sank 148.04% in 2023 and jumped 23239.16% in 2026, its largest moves.
• Core Scientific's Cash from Financing Activities stood at $38.1 million in 2022, then tumbled by 148.04% to -$18.3 million in 2023, then jumped by 3369.23% to $598.2 million in 2024, then plunged by 103.65% to -$21.8 million in 2025, then surged by 4554.25% to $971.4 million in 2026.
• The last three Cash from Financing Activities figures came in at $971.4 million (Q1 2026), -$21.8 million (Q4 2025), and -$5.3 million (Q3 2025), per Business Quant data.